Sangamo Therapeutics filed for Chapter 11 bankruptcy and simultaneously agreed to sell major portions of its platform assets, marking a sharp end to the company’s decades-long ZFN-era strategy. According to the company, Eli Lilly agreed to acquire Sangamo’s capsid delivery, ZFN, modular integrase (MINT) platform, and its prion disease program (ST-506), while Astellas agreed to take on Sangamo’s Fabry disease program (isaralgagene civaparvovec, ST-920). The asset sale structure includes “stalking horse” bids for an eventual bankruptcy auction and excludes several other programs expected to remain available to bidders. For the market, the filing raises immediate questions about platform continuity, capsid and delivery IP stewardship, and how clinical programs outside the sold packages will be funded or partnered going forward.